InternationalUSRemember you can easily switch between MIP US and MIP International at any time

European Commission claims pharma competition success

Legal Media Group

The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission

In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was conducted in 2008 to 2009.

That came as the total number of settlements reached 120 in 2011,...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here


Managing IP


ManagingIP profile

RT @twobirdsIP: Italy: Upcoming rules concerning contributory/indirect infringement and patent infringement exceptions:

Oct 26 2016 04:19 ·  reply ·  retweet ·  favourite
ManagingIP profile

More on Maria Pallante & US Copyright Office

Oct 26 2016 03:45 ·  reply ·  retweet ·  favourite
ManagingIP profile

Our team are on the way to #aiplaAM16 in Washington DC! Please come by stand #23, say hello, pick up some goodies a…

Oct 26 2016 10:44 ·  reply ·  retweet ·  favourite
More from the Managing IP blog

Read this year's AIPPI Congress News - published daily by Managing IP direct from the AIPPI Annual Meeting in Milan

null null null

October 2016

10 issues to watch at the PTAB

Last month marked the fourth anniversary of Patent Trial and Appeal Board proceedings becoming available. While early cases suggested that the Board would be a graveyard for patents, in the past year a more nuanced picture has emerged. Michael Loney identifies 10 issues to watch

Most read articles